Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

Y0000520

Nevirapine (anhydrous)

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Nevirapine, 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2′,3′-e][1,4]diazepin-6-one

Sign Into View Organizational & Contract Pricing

Select a Size

30 MG
$118.00

$118.00

Check Cart for Availability
Request a Bulk Order
All Photos(1)

Select a Size

Change View
30 MG
$118.00

About This Item

Empirical Formula (Hill Notation):
C15H14N4O
CAS Number:
129618-40-2
Molecular Weight:
266.30
MDL number:
MFCD00866928
UNSPSC Code:
41116107
PubChem Substance ID:
329831001
NACRES:
NA.24

$118.00

Check Cart for Availability
Request a Bulk Order

grade

pharmaceutical primary standard

API family

nevirapine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CC1=CC=NC2=C1NC(C(C=CC=N3)=C3N2C4CC4)=O

InChI

1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)

InChI key

NQDJXKOVJZTUJA-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

application

Nevirapine (anhydrous) EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

NNRTI (non-nucleoside reverse transcriptase inhibitor) of HIV-1
Nevirapine is an allosteric, non-nucleoside inhibitor of HIV reverse transcriptase (NNRTI). The Ki for inhibition of wild-type RT by Nevirapine is 200 nM.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Y0000521

Nevirapine for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0001499

Nevirapine hemihydrate, European Pharmacopoeia (EP) Reference Standard

1460703

Nevirapine anhydrous, United States Pharmacopeia (USP) Reference Standard

1460714

Nevirapine hemihydrate, United States Pharmacopeia (USP) Reference Standard

1460725

Nevirapine Related Compound A, United States Pharmacopeia (USP) Reference Standard

1460736

Nevirapine Related Compound B, United States Pharmacopeia (USP) Reference Standard

1460747

Nevirapine Related Compound C, United States Pharmacopeia (USP) Reference Standard

PHR1760

Nevirapine Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1761

Nevirapine Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1762

Nevirapine Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

Storage Class

11 - Combustible Solids

wgk_germany

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ebrahim Bera et al.
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 102(11 Pt 1), 855-859 (2012-11-03)
The package insert for nevirapine (NVP) cautions use in HIV-infected women (including pregnant women) with CD4 counts ≥250 cells/µl. However, recent studies showed that the CD4 count of pregnant women receiving antiretroviral therapy (ART) was not predictive of NVP toxicity.
Patrice Muret et al.
Therapie, 66(3), 187-195 (2011-08-09)
Nevirapine, a HIV non nucleosidic reverse transcriptase inhibitor, displays an inter-individual variability in its pharmacokinetics parameters, related to its hepatic metabolism. Based on literature, is the nevirapine therapeutic drug monitoring relevant? In naïve and pre-treated HIV infected patients, the probability
Ushma Mehta et al.
The Lancet. Infectious diseases, 7(11), 733-738 (2007-10-27)
The non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz and nevirapine are chemically distinct, but both may cause cutaneous hypersensitivity and hepatotoxicity. We reviewed the literature to assess the evidence for cross-reactivity between nevirapine and efavirenz. All papers, abstracts, or presentations, regardless
Nathan Ford et al.
AIDS (London, England), 27(7), 1135-1143 (2013-01-10)
The risk of adverse drug events associated with nevirapine (NVP) is suggested to be greater in pregnant women. We conducted a systematic review and meta-analysis of severe adverse events in HIV-positive women who initiated NVP while pregnant. We searched six
M Popovic et al.
Handbook of experimental pharmacology, (196)(196), 437-451 (2009-12-19)
Treatment of HIV-1 infections with nevirapine is associated with skin and liver toxicity. These two organ toxicities range from mild to severe, in rare cases resulting in life-threatening liver failure or toxic epidermal necrolysis. The study of the mechanistic steps
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service